COVID-19: Vaccine Information, Visitor Information and What to Expect

Montlake Bridge Closure: Learn about detours to Seattle Children’s when the Montlake Bridge closes during several weekends this fall.

Learn about Seattle Children’s Health Equity and Anti-Racism Action Plan, a message from Dr. Jeff Sperring, CEO.

Current Research Studies

Cancer – ADVL1312: Phase 1/2 Study of AZD1775 in Combination with Oral Irinotecan in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors

Condition or Therapy:

Solid tumors

Category:

Cancer and blood disorders

What is the goal of this study?

The goal of this study is to discover the maximum tolerated dose of adavosertib with irinotecan.

Who can join the study?

This study might be a good fit for children and young adults who:

Are 1 to 21 years old
Have relapsed or refractory solid tumors, neuroblastoma, medulloblastoma or rhabdomysarcoma

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Looking for a Researcher?

Name: First Name Last Name
Area of Focus: Research Center:

©1995–2021 Seattle Children’s Hospital

4800 Sand Point Way NE,

Seattle,

WA

98105

206-987-2000

866-987-2000 (toll-free)

206-987-0391 (TTY)

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.